Compare Jones Lang LaSalle Inc (JLL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Jones Lang LaSalle Inc trades at $309.04 (market cap $13.58B), while Travere Therapeutics Inc. Common Stock trades at $54.68 (market cap $5.02B). The key difference: Jones Lang LaSalle Inc is far larger — about 2.7× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| JLL | TVTX | |
|---|---|---|
Market Cap | $13.58B | $5.02B |
Volume | 414,312 | 2,060,842 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $67.52 |
52-Week Low | $280.16 | $26.79 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $16.34B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $301.49, up 1.06% today, with a bearish technical signal but strong fundamentals. Revenue grew to $26.12B in 2025, with net income reaching $792.10M and a 3.64% net margin. The stock is supported by a 58.33% analyst buy rating and a $450.50 consensus price target. Recent news highlights growth in property acquisitions and financing deals, such as the $406M Trammell Crow Center financing announced on September 24, 2026.
The outlook is positive due to consistent earnings beats, robust cash flow growth, and strategic expansions in data centers and real estate services. Risks include market volatility, competitive pressures, and economic sensitivity. With a P/E of 14.16, the stock appears undervalued relative to growth prospects, offering potential upside if operational momentum continues.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
